Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Apr 10, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 14, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001878313-26-000046
Filed / recorded
Apr 14, 2026, 4:44 PM UTC
Added to OQRO
Oct 8, 2026, 2:06 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
MAIA Biotechnology, Inc.
Issuer CIK
1878313
Ticker
MAIA
Reporting person
Sergei Gryaznov
Relationship
Officer
Officer title
Chief Scientific Officer
Security
Stock Options
Table
Derivative (Table II)
Transaction date
Apr 10, 2026
Transaction code
A
Shares / units
400,000
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
400,000
Ownership form
Direct
Amendment
No
Footnotes from the filing
The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.